Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin vs sitagliptin added to metformin in type 2 diabetes
IRCT20160625028627N3Phase 2Completed
- Sponsor
- Kurdistan University of Medical Sciences
- Start
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial in type 2 diabetes mellitus (T2DM) comparing Empagliflozin + metformin with Sitagliptin + metformin (2 arms). Primary endpoints: Serum fetuin-A level and Insulin resistance. Started Jun 2025; status: completed.
02
Drugs
empagliflozinsitagliptinmetformin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on IRCT20160625028627N3.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20160625028627N3.